Background and purpose: Alternative splicing is an important regulation mechanism of gene expression. Aberrant alternative splicing is associated with dysregulation of the cell cycle

activation of oncogenes and inactivation of the tumor suppressor genes. Thus

it is closely correlated with the pathogenesis and progression of various tumors. DNA methylation is an important part of epigenetic phenomena. Aberrant methylation of the gene promoter can result in gene silencing. Hypermethylation of tumor suppressor genes and DNA repair genes correlates with the onset of many different cancers. Additionally

DNA methylation acts as a pivotal factor for alternative splicing. Aberrant methylation disrupts the stabilization of the alternative splicing. This study investigated the promoter methylation and expression of RNA binding protein

fox-1 homolog 1 (RBFOX1) gene in esophageal squamous cell carcinoma (ESCC)

and to elucidate its role in ESCC. Methods: MassARRAY approach and RT-PCR were used respectively to examine the methylation level of RBFOX1 gene and its expression at mRNA level in tumors and corresponding adjacent normal tissues. The correlation between methylation level and clinicopathological features was analyzed. Results: RBFOX1 methylation level and mRNA expression in tumor tissues were significantly lower than those in corresponding adjacent normal tissues (41.8% vs 68.3%

P0.01). No significant correlation was observed between methylation level and clinicopathological features. The cut-off (33.6%) was calculated as the mean of the normal samples to which we applied 2.5 SD. According to the cut-off value

the object of the study was divided into two groups. The methylation level lower than the cut-off was defined as group 1; methylation level higher than the cut-off was defined as group 2. The 5-year overall survival rates of the two groups were 57.0% and 35.7%

respectively (P=0.06); 5-year progression-free survival rates were 48.7% and 28.9%

respectively (P=0.03). However

the multivariate analysis results indicated that TNM stage was the independent factor of prognosis.Conclusion: The methylation level and mRNA expression of RBFOX1 in tumor specimens are significantly lower than those in corresponding adjacent normal tissues. The methylation level of the RBFOX1 promoter is not an independent factor of prognosis.